HC Wainwright Has Strong Forecast for UNCY FY2024 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Research analysts at HC Wainwright lifted their FY2024 earnings per share estimates for Unicycive Therapeutics in a report released on Thursday, November 14th. HC Wainwright analyst E. Arce now expects that the company will post earnings of ($0.11) per share for the year, up from their previous forecast of ($0.12). HC Wainwright has a “Buy” rating and a $2.50 price target on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ FY2025 earnings at ($0.34) EPS, FY2026 earnings at ($0.22) EPS, FY2027 earnings at $0.02 EPS and FY2028 earnings at $0.53 EPS.

Separately, Benchmark reissued a “speculative buy” rating and issued a $3.00 price target on shares of Unicycive Therapeutics in a report on Friday, September 6th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $5.13.

Unicycive Therapeutics Trading Up 6.6 %

Shares of NASDAQ:UNCY opened at $0.49 on Monday. The business’s 50 day moving average is $0.43 and its 200-day moving average is $0.54. The firm has a market capitalization of $50.34 million, a PE ratio of -0.50 and a beta of 2.29. Unicycive Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.82.

Institutional Trading of Unicycive Therapeutics

Large investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in shares of Unicycive Therapeutics in the 3rd quarter worth approximately $29,000. Walleye Capital LLC acquired a new stake in shares of Unicycive Therapeutics in the 3rd quarter valued at $2,040,000. Acuta Capital Partners LLC acquired a new position in shares of Unicycive Therapeutics during the third quarter valued at $807,000. Great Point Partners LLC acquired a new position in Unicycive Therapeutics in the third quarter valued at approximately $3,491,000. Finally, Bleakley Financial Group LLC acquired a new position in Unicycive Therapeutics in the third quarter valued at approximately $33,000. 40.42% of the stock is currently owned by institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.